EC
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications |  | 2024 | 55 | 50 | ||
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | 2023 | 28 | 12 | ||
| Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins | iScience | | 2023 | 66 | 21 | ||
| Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer model | AACR Annual Meeting 2023 | | 2023 | 42 | 40 | ||
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | 2022 | 54 | 31 | ||
| Immortalised human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology | Molecular therapy. Methods & clinical development | | 2022 | 130 | 53 | ||
| Local sustained GM-CSF delivery by genetically engineered encapsulated cells enhanced both cellular and humoral SARS-CoV-2 spike-specific immune response in an experimental murine spike DNA vaccination model | Vaccines | | 2021 | 190 | 121 | ||
| A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein | Vaccines | | 2021 | 246 | 84 | ||
| An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | | 2020 | 431 | 263 |
